Roche earned the CE-IVD mark for its Cobas MTB-RIF/INH test, an assay used to detect antibiotic resistance mutations in the Mycobacterium tuberculosis DNA.

The assay runs on the company’s Cobas 6800/8800 automated molecular platforms and is part of its mycobacteria test menu.

The highly-sensitive test helps clinicians in speeding up the diagnosis and treatment of TB by detecting antimicrobial resistance.